Patents by Inventor Arlene Helen Sharpe

Arlene Helen Sharpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody molecules to PD-1 and uses thereof
    Patent number: 11827704
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: November 28, 2023
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1
    Publication number: 20230013364
    Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: December 13, 2021
    Publication date: January 19, 2023
    Inventors: Glenn Dranoff, Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
    Publication number: 20230000964
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 5, 2023
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
    Patent number: 11413340
    Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 16, 2022
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
    Publication number: 20210284737
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 23, 2020
    Publication date: September 16, 2021
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • Antibody molecules to PD-L1 and methods of treating cancer
    Patent number: 10851165
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: December 1, 2020
    Assignees: Novartis AG, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20200339689
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: July 10, 2020
    Publication date: October 29, 2020
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 10752687
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: August 25, 2020
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
    Publication number: 20190000944
    Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Application
    Filed: December 21, 2016
    Publication date: January 3, 2019
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1
    Publication number: 20180222982
    Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 9, 2018
    Inventors: Glenn Dranoff, Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
    Publication number: 20180186882
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 5, 2018
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20180155427
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 6, 2017
    Publication date: June 7, 2018
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to PD-L1 and uses thereof
    Patent number: 9988452
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: June 5, 2018
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 9815898
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20170247456
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Applicants: Novartis AG, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 9683048
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: June 20, 2017
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
    Publication number: 20160108123
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 13, 2015
    Publication date: April 21, 2016
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20150210769
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 30, 2015
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey